Sermorelin and thyroid medication need to be reviewed together. The reason for thyroid treatment matters, along with recent blood tests. Levothyroxine replaces thyroid hormone; taking it doesn't settle whether sermorelin is a good fit. Starting sermorelin also doesn't automatically mean changing that thyroid prescription.
The main question is how the two hormone systems affect each other. Evidence from people receiving growth hormone explains why thyroid follow-up matters. It does not supply a ready-made levothyroxine adjustment for someone prescribed sermorelin.
Sermorelin and thyroid medication: the diagnosis matters
Sermorelin copies part of growth hormone-releasing hormone, or GHRH, the body's signal to release growth hormone. It acts on the pituitary, a small gland at the base of the brain. That gland also sends signals to the thyroid, which helps regulate how the body uses energy.
Primary hypothyroidism means the thyroid itself is underactive. Central hypothyroidism means the thyroid lacks enough stimulation from the pituitary or the brain region controlling it. Both can involve thyroid replacement, but their blood tests are interpreted differently.
That is why “I take thyroid medicine” leaves an important question unanswered: what condition is it treating? A history of pituitary surgery or radiation adds context that the medicine's name alone cannot provide.
There is also a difference between replacing thyroid hormone and blocking its production. Ireland's archived Geref diagnostic label says untreated low thyroid function or anti-thyroid medicines can affect the growth-hormone response. Anti-thyroid medicines reduce thyroid-hormone production; levothyroxine replaces it.
Valcavi's 1986 study in Clinical Endocrinology adds a useful distinction. In 14 people with primary hypothyroidism, thyroid replacement improved the growth-hormone response to a GHRH test. It did not establish a thyroid dose-change rule for ongoing sermorelin treatment.
What the older GHRH study actually measured
A frequently cited paper by Khorram and colleagues in The Journal of Clinical Endocrinology & Metabolism in 1997 followed 19 older adults. They received four weeks of placebo, an inactive comparison treatment, followed by 16 weeks of a GHRH analogue. An analogue is a related molecule with a changed structure.
The molecule was [Nle27]GHRH(1–29)-NH2, with one protein building block changed. It was not ordinary sermorelin. The study reported growth hormone, IGF-1, a blood marker of growth-hormone activity, and several metabolic measurements.
Its abstract lists no measurement of thyroid-stimulating hormone, or TSH, the pituitary's message to the thyroid. It also lists no free T4, the portion of the thyroid hormone thyroxine not bound to blood proteins, and no thyroid-replacement dose outcome.
Those missing measurements matter. A rise in a growth-hormone marker cannot tell us whether thyroid replacement stayed adequate. The abstract also does not describe anyone taking thyroid replacement. It was not a study of people combining sermorelin with levothyroxine.
Why growth-hormone replacement raises a different question
Growth-hormone treatment supplies the hormone itself. Sermorelin asks the pituitary to release it. The sermorelin versus HGH comparison explains that distinction; HGH means human growth hormone.
Glynn and colleagues studied 20 adult men with hypopituitarism, meaning reduced production of pituitary hormones. Their 2017 Clinical Endocrinology paper examined growth-hormone replacement, not sermorelin. Its abstract reports that average free T4 fell while TSH remained unchanged.
This helps explain why a thyroid result needs context. It does not tell us how often a person taking sermorelin would need a thyroid prescription changed. The drug, diagnosis and population differ.
The Endocrine Society's 2016 hypopituitarism guideline addresses this directly for growth-hormone replacement. It recommends thyroid monitoring and says people with central hypothyroidism already taking levothyroxine may need more when growth hormone begins. That recommendation belongs to that treatment setting. It cannot be converted into an automatic increase when sermorelin is prescribed.
Why free T4 can matter alongside TSH
In central hypothyroidism, TSH alone can miss an inadequate thyroid-hormone level. The same guideline recommends measuring both TSH and free T4 to evaluate the condition. It recommends against using TSH to adjust thyroid replacement in those patients.
That is a specific point about pituitary-related thyroid disease. It doesn't mean every person taking levothyroxine has central hypothyroidism, or that their usual thyroid monitoring has been wrong.
For a sermorelin review, the useful record connects the diagnosis, medicine and dated test results. A result from before a thyroid dose change answers a different question from one obtained afterward. The clinician managing thyroid replacement decides which repeat tests are needed and when.
There is no thyroid target or testing interval established by the studies discussed here for everyone taking compounded sermorelin. A follow-up plan has to fit the person's diagnosis rather than borrow a timetable from another drug's study.
What a coordinated prescription plan covers
The thyroid part of the visit can stay practical:
- The diagnosis: whether the problem began in the thyroid or involves pituitary disease.
- The actual medicines: the thyroid product, prescribed amount, recent changes and other hormone treatments.
- The starting record: recent thyroid results, their dates and whether the prescription was stable when they were drawn.
- The follow-up: who reviews new results, assesses symptoms and makes any medication changes.
That is one part of the broader questions to ask before sermorelin. Its purpose here is to keep two prescribers from making separate decisions without the same information.
A spacing rule between the medicines cannot be inferred from these hormone studies. None tested whether sermorelin changes levothyroxine absorption. The existing thyroid prescription has its own administration instructions; a new peptide request does not replace them.
For other reactions and warning symptoms, the sermorelin side-effects guide covers the wider safety discussion. The prescriber sets sermorelin's actual dose and any changes. A thyroid medication adjustment belongs with the clinician managing that condition.
The product history and today's review
Sermorelin prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication. It is different from the FDA-approved sermorelin product once marketed as Geref, which has since been discontinued. The formulation offered here is not FDA-approved.
FDA's March 4, 2013 notice records Geref approvals in 1990 and 1997, withdrawn effective June 18, 2009. It found neither product was withdrawn for safety or effectiveness reasons.
As of November 12, 2026, the day this article was written, HHS's October 30 notice describes a draft compounding policy. Its six-peptide list does not name sermorelin; all ten conditions apply to the listed substances. The HHS policy explainer covers those conditions.
A licensed provider may still prescribe — that decision is between you and your doctor.
At Promise, a licensed provider reviews every request, and not everyone qualifies. The thyroid diagnosis, current prescription and follow-up plan belong in that review together.





